MARKET

XERS

XERS

Xeris Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.695
+0.135
+8.65%
After Hours: 1.890 +0.195 +11.50% 16:12 04/03 EDT
OPEN
1.620
PREV CLOSE
1.560
HIGH
1.790
LOW
1.609
VOLUME
276.92K
TURNOVER
--
52 WEEK HIGH
12.98
52 WEEK LOW
1.420
MARKET CAP
63.68M
P/E (TTM)
-0.3535
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XERS stock price target is 13.20 with a high estimate of 18.00 and a low estimate of 10.00.

EPS

XERS News

More
  • NRZ, TWO, SRNE and CNX among midday movers
  • Seeking Alpha - Article · 23h ago
  • Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Business Wire · 03/27 22:30
  • Xeris Pharma cuts Gvoke copay amid Covid-19
  • seekingalpha · 03/27 01:27
  • Xeris Pharmaceuticals Announces $0 Copay for Gvoke PFS for People With Diabetes
  • Business Wire · 03/26 21:15

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About XERS

Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides, proteins, antibodies and small molecules using commercially-available syringes, auto-injectors, multi-dose pens and infusion pumps. The Company is developing its lead product candidate, the Glucagon Rescue Pen, for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.
More

Webull offers kinds of Xeris Pharmaceuticals Inc stock information, including NASDAQ:XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions.